Ramin Sarrafizadeh, MD
Retina Specialist · Colorado Springs, CONPI 1700813391
Payments from drug & device makers
What this record shows
The money is spread across several categories — other (51.6%), ownership interests and food and beverage — rather than concentrated in one kind of arrangement. US Retina LLC accounts for 92.6% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2023 at $3,346 and has fallen 98.4% since, to $53 in 2025.
Across 27 payments — averaging $238.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- US Retina LLC$6K
- AbbVie$171
- Eyepoint US, Inc.$134
- Genentech USA, Inc.$63
- Ocular Therapeutix, Inc.$48
- Apellis Pharmaceuticals, Inc.$30
- plus $33 from 2 others
Across 129 payments — averaging $13,204 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bayer$1.2M
- Ocular Therapeutix, Inc.$414K
- Alimera Sciences, Inc.$27K
- ANI Pharmaceuticals, Inc.$19K
- Eyepoint US, Inc.$19K
- Novartis$10K
What the payments were for
- Food & beverage$4627%
- Entertainment$160%
- Ownership interest$2,64441%
- Other$3,32652%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| US Retina LLC | 5 | $5,970 |
| AbbVie(2 entities) | 9 | $171 |
| Eyepoint US, Inc. | 3 | $134 |
| Genentech USA, Inc. | 4 | $63 |
| Ocular Therapeutix, Inc. | 2 | $48 |
| Apellis Pharmaceuticals, Inc. | 1 | $30 |
| Genentech, Inc. | 1 | $17 |
| Optos, Inc. | 2 | $16 |
How this compares
$6,449 in reported general payments places this provider in the 55th percentile of 51 retina specialist providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 271 | $8,767 |
| Brimonidine Tartrate | 40 | $1,688 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 92 | $1,459 |
| Ciprofloxacin Hcl | 118 | $1,313 |
| Difluprednate | 16 | $1,077 |
| Ketorolac Tromethamine | 32 | $780 |
| Latanoprost | 28 | $343 |
| Timolol Maleate | 31 | $188 |
| MoxifloxacinMoxifloxacin Hcl | 11 | $153 |
| ErythromycinErythromycin Base | 12 | $137 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Colorado Springs
- Adam MartidisColorado Springs$15K
- James LuuColorado Springs$11K
- Cecinio RonquilloColorado Springs$10K
- Stanford TaylorColorado Springs$5K
- Mark ChittumColorado Springs$4K
- Amar ManninaColorado Springs$2K
- Jonathan WilliamsColorado Springs$367
- Murtaza AdamParker$548K
- Alan KimuraDenver$546K
- Brian JoondephDenver$92K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.